Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180196 | 0.83 | GAA (0.41) | L3MBTL1TDP1KMT2AMEN1LMNA | |
| SCHEMBL30823619 | 0.83 | GAA (0.41) | L3MBTL1TDP1KMT2AMEN1LMNA | |
| SCHEMBL14362225 | 0.83 | BCL2L1 (0.40) | L3MBTL1TDP1PTGS1PTGS2RAB9A | |
| SCHEMBL9221268 | 0.81 | TAAR1 (0.42) | PTGS1PTGS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15530300 | 0.80 | ALDH1A1 (0.45) | SMN1; SMN2KMT2AMEN1LMNAHPGD | |
| SCHEMBL30723203 | 0.77 | GAA (0.39) | L3MBTL1TDP1KMT2AMEN1LMNA | |
| SCHEMBL29975298 | 0.77 | GAA (0.39) | L3MBTL1TDP1KMT2AMEN1LMNA | |
| SCHEMBL816601 | 0.77 | GAA (0.39) | L3MBTL1TDP1KMT2AMEN1LMNA | |
| SCHEMBL5718625 | 0.77 | GAA (0.39) | L3MBTL1TDP1KMT2AMEN1LMNA | |
| SCHEMBL30716894 | 0.77 | AMY1A (0.44) | L3MBTL1TDP1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011012961-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CLOPIDOGREL BISULFATE | ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) | 2011-02-03 | — | — | WO | claimed |
| EP-2585428-B1 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-05-10 | — | — | EP | disclosed |
| US-8981121-B2 | Process for the preparation of nitrogen substituted aminotetralins derivatives | UCB PHARMA GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2585428-A2 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB Pharma GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | UCB PHARMA GMBH (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2011161255-A2 | NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES | UCB PHARMA GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011012961-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CLOPIDOGREL BISULFATE | ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) | 2011-02-03 | — | — | WO | disclosed |
| WO-2007144729-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CLOPIDOGREL | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-12-21 | — | — | WO | disclosed |
| EP-1203771-A1 | REMEDIES OR PREVENTIVES FOR FREQUENT URINATION OR URINARY INCONTINENCE | TORAY INDUSTRIES, INC. (JP) | 2002-05-08 | — | — | EP | disclosed |
| US-5166218-A | Antilipemic agents or antiglycemic agents | HOFFMANN-LA ROCHE INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5064863-A | Catabolic activity, obesity, diabetes | HOFFMANN-LA ROCHE INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-4219559-A | N-Heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | AANAT, AADAT, ASNS | L3MBTL1 4047/4885TDP1 2012/4885PTGS1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.